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a b s t r a c t
The results of several new clinical trials that compared the effectiveness of entecavir (ETV)
treatment with that of adefovir (ADV) treatment in patients with chronic hepatitis B (CHB)
were published in recent years. However, the numbers of patients included in these clinical
trialswere too small to drawa clear conclusion as towhether ETV ismore effective thanADV.
Therefore, a new meta-analysis was needed to compare ETV with ADV for the treatment of
CHB. A search of the Cochrane Central Register of Controlled Trials (CCTR), MEDLINE, the
Science Citation Index, Embase, the China National Knowledge Infrastructure (CNKI), and
theWanfangDatabase for relevant studies published between 1966 and 2010was performed.
Trials comparing the use of ETV and ADV for the treatment of CHB were assessed. Of the
2,358 studies screened, 13 randomized controlled clinical trials comprising 1,230 patients
(ETV therapy, 621; ADV therapy, 609) were analyzed. The serum hepatitis B virus (HBV) DNA
clearance rate obtained in patients treated with ETV was signiﬁcantly higher than that in
patients treated with ADV at the 24th and 48th weeks of treatment (24 weeks: 59.6% vs.
31.8%, relative risk [RR], 1.82, 95% CI: 1.49–2.23; 48 weeks: 78.3% vs. 50.4%, RR, 1.61, 95%
CI: 1.32–1.96). The serum HBeAg clearance rate, the HBeAg seroconversion rate, and the
ALT normalization rate obtained for patients treated with ETV were also higher than the
corresponding values for patients treated with ADV at the 48th week of treatment. The
safety proﬁles were similar between patients treated with ETV and those treated with ADV.The evidence reviewed in this meta-analysis suggests that patients with hepatitis B have
a greater likelihood of achieving a viral response and a biomedical response when treated
treat
imately 2 billion people worldwide have been infected with
12 Ewith ETV than when
Introduction
© 20Hepatitis B is a viral infection that attacks the liver and can
cause both acute and chronic disease. Hepatitis B puts people
∗ Corresponding author at: Laboratory Animal Center, Xi’an Jiaotong Un
E-mail address: sihaizhao@mail.xjtu.edu.cn (S.-H. Zhao).
1413-8670 © 2012 Elsevier Editora Ltda.
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Este é um artigo Open Access sob a licençaed with ADV.
at a high risk of death from liver cirrhosis and cancer. Approx-
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDiversity School of Medicine, Shaanxi 710061, China.
hepatitis B virus (HBV), and approximately 350 million live
with chronic infection.1 In mainland China, a nationwide sur-
vey in 2006 showed that the prevalence of hepatitis B surface
 de CC BY-NC-ND
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ntigen (HBsAg)was approximately 1.5% in children under the
ge of 8 years and 7.18% in thenationwide population between
he ages of 1 and 59 years.2 HBV has become the most impor-
ant cause of chronic hepatitis and end-stage liver disease in
hina.
Adefovir (ADV) and entecavir (ETV) are nucleos(t)ide
nalogs that have been approved for the treatment of chronic
BV infections for a number of years. ETV is associated with
delayed development of resistance and a low incidence of
esistance in treatment-naïve patients. In addition, this drug
xhibits antiviral activity against lamivudine (LAM)-resistant
BV, although ETV exhibits some degree of cross-resistance.3
n recent years, a number of clinical trials have compared
he efﬁcacy and adverse effects of ETV and ADV for the
reatment of chronic hepatitis B (CHB).4–17 However, these
linical trials have reached inconsistent conclusions. There-
ore, we performed a meta-analysis that included a relatively
arge number of patients. The data for this meta-analysis
ere collected from the Cochrane Central Register of Con-
rolled Trials (CCTR), MEDLINE, the Science Citation Index
SCI), the Excerpta Medica Database (Embase), the China
ational Knowledge Infrastructure (CNKI), the China Biologi-
al Medicine Database (CBM), and the Wanfang Database, and
ere used to compare the efﬁcacy of ETV treatment with that
f ADV treatment in patients with hepatitis B.
aterials and methods
earch strategy
he CCTR, MEDLINE, the SCI, Embase, the CNKI, the CBM,
nd the Wanfang Database were searched to identify random-
zed controlled clinical trials (RCTs) published in the area of
epatitis B and antiviral therapy between 1966 and 2010. The
eywords used in the literature searcheswere hepatitis B, HBV,
ntecavir, adefovir, treatment, and trial.
ata extraction
wo authors (Liu E and Zhao S) independently screened titles
nd abstracts for potential eligibility and reviewed the full
exts to determine ﬁnal eligibility. The data were indepen-
ently extracted from the included trials for quantitative
nalyses, and any disagreementwas subsequently resolved by
iscussion. The quantitative data included sample size; pre-
reatment patient characteristics, including the age range and
ender; type of treatment (ADV or ETV); doses of the drugs;
VRs; HBeAg seroconversion rate; and viral suppression at the
nd of treatment.
nclusion criteria
he inclusion criteria applied were the following: (i) study
esign–the RCT was performed to compare the therapeu-
ic effects of ADV and ETV; (ii) study duration–patients were
reated for 24 or 48 weeks; (iii) language of publication–English
r Chinese; (iv) outcomes measured–HBeAg seroconversion
ate, serum HBeAg clearance rate, serum HBV DNA clearance
ate, and ALT normalization rate. Reports that concerned the2;16(4):366–372 367
same studies were excluded by examining the author list,
institution, sample size, and results.
Outcome measure
The HBeAg seroconversion rate, the serum HBeAg clearance
rate, the serum HBV DNA clearance rate and the ALT nor-
malization rate were used as the main outcome measures to
assess the effects of ADV or ETV treatment in the included
trials. Serum HBeAg clearance or HBV DNA clearance was
deﬁned as a reduction in HBeAg or HBV DNA to undetectable
levels. All analyseswere performedaccording to the intention-
to-treat method.
Assessment of study quality
Two authors (WeiK and Li Y) independently and informally
assessed the study quality by treatment type (ADV or ETV);
doses; rates of response; study population, eligibility crite-
ria and participation rate; reasons for failure to complete the
study; covariates and cofounders with appropriate techniques
for control; acknowledgement of commercial support; and sta-
tistical methodology.
Statistical analysis
In this meta-analysis, a random- or ﬁxed-effects model was
adopted because of the anticipated variability among trials
with respect to the patient populations.18,19 Meta-analysis
was performed using ﬁxed-effects or random-effects model,
depending on the absence or presence of signiﬁcant hetero-
geneity. When heterogeneity due to variability was signiﬁcant
(p>0.1), a random-effects model was used; otherwise the
ﬁxed-effects model was used. The measure of association
used in this meta-analysis was the relative risk (RR) with a
95% conﬁdence interval (CI). The summary RR with the 95% CI
was calculated using RevMan 5.0 with the random- or ﬁxed-
effects model (Review Manager Version 5.0 for Windows; The
Cochrane Collaboration–Oxford, UK). The result was assumed
to be statistically signiﬁcant when the 95% CI did not include
one.
Heterogeneity was assessed using a chi-square test, and
the quantity of heterogeneity was measured using the I2
statistic.Whenpatientswerediscontinued, thedatawere ana-
lyzed according to the intention-to-treat principle. Patients
who did not achieve the selected endpoints were considered
to have failed therapy. The total number of patients was used
as the denominator.
Results
Literature research
Of the 2,358 articles identiﬁed through the electronic database
search, 13 RCTs matched the selection criteria. 4–17 There was
unanimity between the two authors regarding the selection of
relevant articles (Sihai Zhao and Enqi Liu) (Fig. 1).
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Table 1 – Pre-treatment patient characteristics for the trials included in the meta-analysis.
References Treatment Sample
size
Sex
Male/Female
Mean agea HBeAg (+)
(n)
HBV DNA
log10
(copies/mL)
ETV or
ADV dose
Treatment-
naïve
(n)
Duration
(weeks)
Ding H4 ETV 20 –/– – 20 >5 0.5mg/d 20 48
ADV 21 21 10mg/d 21
Fan WB5 ETV 32 28/4 39.0± 13.1 32 6.58± 1.29 0.5mg/d – 48
ADV 28 26/2 42.6± 10.4 28 6.41± 1.15 10mg/d
Huang H6 ETV 57 –/– – 41 – 0.5 or 1.0mg/db – 48
ADV 42 22 10mg/d
Jiang YF14 ETV 29 24/5 40.6± 9.3 20 8.28± 8.61 0.5mg/d 17 48
ADV 28 23/5 43.1± 8.1 23 9.07± 9.72 10mg/d 14
Leung N16 ETV 33 20/13 37± 2.4 33 10.26± 0.35a 0.5mg/d 33 48
ADV 32 21/11 32± 2.0 32 9.88± 0.22a 10mg/d 32
Liaw YF17 ETV 99 141/49 52 103 7.52± 0.19a 1.0mg/d – 24
ADV 91 8.16± 0.23a 10mg/d
Lin Q7 ETV 56 43/13 18–65 39 7.94± 1.21 0.5mg/d 37 48
ADV 69 55/14 41 7.56± 1.63 10mg/d 40
Liu L8 ETV 57 –/– 18–65 0 >5 0.5mg/d 57 24
ADV 45 0 10mg/d 45
Wang CH9 ETV 30 19/11 46.9 30 >5 0.5mg/d – 48
ADV 30 21/9 43.1 30 10mg/d
Yang F10 ETV 30 24/6 37± 14 21 6.77± 1.66 0.5mg/d 30 48
ADV 30 26/4 40± 13 18 7.03± 1.79 10mg/d 30
Yang YF11 ETV 68 24/6 37± 14 21 6.77± 1.66 0.5mg/d 30 48
ADV 75 26/4 40± 13 18 7.03± 1.79 10mg/d 30
Zhang YQ12 ETV 50 41/9 16–50 50 – 0.5mg/d – 52
ADV 58 47/11 58 10mg/d
Zou S13 ETV 60 –/– 30–75 30 – 0.5mg/d 60 48
ADV 60 30 10mg/d 60
for rea Expressed as the mean±SE.
b 0.5 or 1.0mg/d, 0.5mg/d for treatment-naïve patients and 1.0mg/d
Clinical trial characteristics
The patients included in the 13 trials were randomly assigned
to the ETV or ADV therapy groups. Of the 1,230 patients, 621
were treated with ETV, and 609 were treated with ADV. All
included trials were single-center studies. ETV was used at
Potential articles and abstracts
found through various keyword
combinations (n = 2,358)
Exclusion by title and abstract
screening (n = 2,336)
Potential eligible articles and
abstracts (n = 22)
Replicated report (n = 3)
Not RCT (n = 5)
Did not evaluate our studied
primary endpoints (n = 1)
RCTs included in our analysis (n = 13)
Fig. 1 – Analysis of the search results. RCT, randomized
control clinical trials.treated patients.
a ﬁxed dose of 0.5mg/day except in the studies by Huang
et al., in which the dose was 1mg/day for treatment-naïve
patients. ADV was used at a ﬁxed dose of 10mg/day. The base-
line characteristics of the patients of the four included trials
are summarized in Table 1.
Comparison of ETV and ADV therapies for the treatment
of hepatitis B in Chinese patients
Serum HBV-DNA clearance rates
In this study, the combined serum HBV-DNA clearance rate
in the ETV treatment group was higher than that in the ADV
group at the 24th and 48th weeks of treatment (59.6% vs. 31.8%,
RR=1.82, 95% CI: 1.49–2.23, p< 0.01; 78.3% vs. 50.4%, RR=1.61,
95% CI: 1.32–1.96, p< 0.01, respectively) (Fig. 2).
Serum HBeAg clearance rates
The serum HBeAg clearance rate was also analyzed in this
study. Higher serum HBeAg clearance rates were observed
in patients treated with ETV than in patients treated with
ADV at the 24th and 48th weeks of treatment (16.5% vs. 12.2%,
RR=1.38, 95% CI: 0.72–2.64, p= 0.33; 28.1% vs. 20.8%, RR=1.35,
95% CI: 1.02–1.79, p< 0.05, respectively) (Fig. 3).HBeAg seroconversion rates
The HBeAg seroconversion rates were reported in six trials.
The meta-analysis results showed that the HBeAg serocon-
version rates were greater for patients treated with ETV than
braz j infect d i s . 2012;16(4):366–372 369
Study or subgroup
ETV ADV
Total Total Weight
Risk ratio
M-H, Random, 95% CI
Risk ratio
M-H, Random, 95% CIEventsEvents
40
13
15
49
38
29
15
53
252
57
29
35
99
56
57
30
60
423
17
9
4
15
24
16
7
35
127
42
28
34
91
69
45
30
60
399
15.4%
7.4%
3.8%
11.5%
17.0%
12.7%
6.3%
25.9%
100.0%
1.73 [1.16, 2.60]
1.39 [0.71, 2.73]
3.64 [1.34, 9.87]
3.00 [1.81, 4.97]
1.95 [1.35, 2.82]
1.43 [0.90, 2.29]
2.14 [1.02, 4.49]
1.51 [1.20, 1.91]
1.82 [1.49, 2.23]
1.1.1 24 weeks
Huang H6
Jiang YF14
Leung N16
Liaw YF17
Lin Q7
Liu L8
Wang Z9
Zou S13
Subtotal (95% CI)
Total events
Huang H6
Jiang YF14
Leung N16
Lin Q7
Wang Z9
Yang F10
Yang YF11
Zhang YQ12
Zou S13
Subtotal (95% CI)
Total events
44
17
19
47
22
23
54
45
54
325
Heterogeneity: Tau2 = 0.05; Chi2 = 26.24, df = 8 (p = 0.0010); I2 = 70%
Test for overall effect: z = 4.72 (p < 0.00001)
57
29
35
56
30
30
68
50
60
415
22
12
6
34
14
9
28
45
40
210
42
28
34
69
30
30
75
58
60
426
12.4%
8.0%
4.7%
13.8%
9.6%
7.1%
12.5%
16.3%
15.6%
100.0%
1.47 [1.07, 2.03]
1.37 [0.81, 2.31]
3.08 [1.40, 6.76]
1.70 [1.31, 2.22]
1.57 [1.01, 2.44]
2.56 [1.43, 4.57]
2.13 [1.55, 2.92]
1.16 [0.98, 1.37]
1.35 [1.11, 1.65]
1.61 [1.32, 1.96]
1.1.2 48 weeks
Heterogeneity: Tau2 = 0.03; Chi2 = 10.70, df = 7 (p = 0.15); I2 = 35%
Test for overall effect: z = 5.78 (p < 0.00001)
0.1 0.2 0,5
Favours ADV Favours ETV
1 2 5 10
F
R
p
F
R
pig. 2 – Serum HBV-DNA clearance rates in hepatitis B patients tr
R, relative risk; CI, conﬁdence interval; Test for heterogeneity: c
-value; I2, inconsistency among results; z, statistic with p-value
Study or subgroup
ETV ADV
Total Total WeightEventsEvents
2
4
9
3
18
20
20
39
30
109
2
6
3
3
14
21
23
41
30
115
14.5%
41.5%
21.7%
22.3%
100.0%
1.2.1 24 weeks
Ding H4
Jiang YF14
Lin Q7
Wang Z9
Subtotal (95% CI)
Total events
Heterogeneity: Chi2 = 3.06, df = 3 (p = 0.38); I2 = 2%
Test for overall effect: z = 0.97 (p = 0.33)
4
6
6
17
9
4
20
16
82
20
20
35
39
30
30
68
50
292
4
6
7
6
8
9
15
10
65
21
23
34
41
30
30
75
58
312
6.2%
8.9%
11.3%
9.3%
12.7%
14.3%
22.7%
14.7%
100.0%
1.2.2 48 weeks
Ding H4
Jiang YF14
Leung N16
Lin Q7
Wang Z9
Yang F10
Yang YF11
Zhang YQ12
Subtotal (95% CI)
Total events
Heterogeneity: Chi2 = 10.04, df = 7 (p = 0.19); I2 = 30%
Test for overall effect: z = 2.07 (p = 0.04)
ig. 3 – Serum HBeAg clearance rates in hepatitis B patients treat
R, relative risk; CI, conﬁdence interval; Test for heterogeneity: c
-value; I2, inconsistency among results; z, statistic with p-valueeated with ETV and ADV.
hi-squared statistic with its degrees of freedom (df) and
.
Risk ratio
M-H, Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CI
0.01 0.1
Favours ADV Favours ETV
1 10 100
1.05 [0.16, 6.76 ]
0.77 [0.25, 2.34]
3.15 [0.92, 10.80]
1.00 [0.22, 4.56]
1.38 [0.72, 2.64]
1.05 [0.30, 3.64]
1.15 [0.44, 3.00]
0.83 [0.31, 2.23]
2.98 [1.31, 6.77]
1.13 [0.50, 2.52]
0.44 [0.15, 1.29]
1.47 [0.82, 2.64]
1.86 [0.93, 3.71]
1.35 [1.02, 1.79]
ed with ETV vs. ADV.
hi-squared statistic with its degrees of freedom (df) and
.
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Study or subgroup
ETV ADV
Total Total Weight
Risk ratio
M-H, Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CIEventsEvents
1.3.1 24 weeks
Lin Q7
Wang Z9
Subtotal (95% CI)
Total events
Heterogeneity: Chi2 = 0.02, df = 1 (p = 0.88); I2 = 0%
Test for overall effect: z = 1.48 (p = 0.14)
1.3.2 48 weeks
Ding H4
Fan WB5
Leung N16
Lin Q7
Wang Z9
Zhang YQ12
Subtotal (95% CI)
Total events
Heterogeneity: Chi2 = 5.72, df = 5 (p = 0.33); I2 = 13%
Test for overall effect: z = 1.72 (p = 0.09)
0.02 0.1
Favours ADV Favours ETV
1 10 50
7
2
9
39
30
69
3
1
4
41
30
71
74,5%
25.5%
100.0%
2.45 [0.68, 8.82]
2.00 [0.19, 20.90]
2.34 [0.76, 7.18]
1
5
5
13
4
13
41
20
32
35
39
30
50
206
1
4
7
5
5
7
29
21
28
34
41
30
58
212
3.4%
14.9%
24.7%
17.0%
17.4%
22.6%
100.0%
1.05 [0.07, 15.68]
1.09 [0.33, 3.68]
0.69 [0.24, 1.98]
2.73 [1.07, 6.95]
0.80 [0.24, 2.69]
2.15 [0.93, 4.98]
1.46 [0.95, 2.25]
Fig. 4 – HBeAg seroconversion rates, subgroup analysis of ETV vs. ADV in the treatment of hepatitis B patients.
RR, relative risk; CI, conﬁdence interval; Test for heterogeneity: chi-squared statistic with its degrees of freedom (df) and
p-value; I2, inconsistency among results; z, statistic with p-value.for patients treated with ADV at the 24th and 48th weeks of
treatment, but there was no statistically signiﬁcant difference
(13.0% vs. 5.6%, RR=2.34, 95% CI: 0.76–7.18, p= 0.14; 19.9% vs.
13.7%, RR=1.46, 95%CI: 0.95–2.25, p= 0.09, respectively) (Fig. 4).
Serum ALT normalization
Analysis of the combined data from the included studies
regarding ALT normalization was also performed to compare
the effect of ETV therapy with the effect of ADV therapy. The
combinedALTnormalization rateswere signiﬁcantly higher in
the ETV treatment groups (68.6% vs. 59.3%, RR=1.17, 95% CI:
1.03–1.22, p= 0.02; 86.2% vs. 78.0%, RR=1.11, 95% CI: 1.04–1.19,
p< 0.01, respectively) (Fig. 5).
Safety proﬁle
Treatment was generally safe and well tolerated. The most
frequently reported adverse events included headache, upper
respiratory tract infection, nasopharyngitis, pyrexia, and ﬂu-
like symptoms. The differenceswith respect to overall adverse
events or intercurrent illnesses reported in the included trials
betweenpatients treatedwith ETVand those treatedwithADV
were not signiﬁcant.
Discussion
Hepatitis B is a serious epidemic disease. Liver failure due
to chronic hepatitis B is an unsolved medical problem that
results in a signiﬁcant number of deaths. Therefore, treatment
strategies for hepatitis B are urgently needed. Lamivudine
(LAM), ADV, and ETV are nucleos(t)ide analogs that have been
approved for the treatment of chronic HBV infection. Thesedrugs have inhibitory effects onHBVpolymerase/reverse tran-
scriptase activity. LAMwas the ﬁrst drug to be approved for the
treatment of chronic HBV infection and has been used exten-
sively formore thanadecadewith anexcellent safety record.20
However, prolonged treatment with LAM is limited by the high
rates of resistance and by the loss of therapeutic efﬁcacy. More
potent agents with lower rates of resistance were sought to
provide sustained long-term suppression of viral replication
and to prevent the progression of liver disease.
Clinical studies have shown that ADV monotherapy, ADV
add-on LAM combination therapy, and ETV monotherapy
are all effective in both compensated and decompensated
patients infected with LAM-resistant viruses.21,22 Recently, a
number of clinical trials have compared the antiviral efﬁcacies
of ETV and ADV in patients with CHB infection, but these trials
reached inconsistent conclusions. Therefore, a meta-analysis
that included a large number of patients was performed to
compare ETV with ADV for the treatment of hepatitis B. In
comparison with ADV, ETV resulted in higher HBeAg sero-
conversion rates, serum HBeAg clearance rates, serum HBV
DNA clearance rates, and ALT normalization rates in hepatitis
B patients in this study. The serum HBV DNA clearance rate
obtained in patients treated with ETV was signiﬁcantly higher
than that in patients treated with ADV at the 24th and 48th
weeks of treatment (24weeks: 59.6% vs. 31.8%; 48weeks: 78.3%
vs. 50.4%). The serum HBeAg clearance rate, HBeAg serocon-
version rate, and ALT normalization rate obtained for patients
treated with ETV were also higher than those for patients
treated with ADV at the 48th week of treatment.
Successful antiretroviral therapymay slowdiseaseprogres-
sion and reduce the incidence of liver-associated mortality.
In this study, patients with hepatitis B had a greater likeli-
hood of achieving a viral response and a biochemical response
braz j infect d i s . 2012;16(4):366–372 371
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Ding H4
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Lin Q7
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Zou S13
Subtotal (95% CI)
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Fig. 5 – Serum ALT normalization rates, subgroup analysis of ETV vs. ADV in the treatment of hepatitis B patients.
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